Meta-Analysis
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Oct 15, 2022; 14(10): 2061-2076
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.2061
Table 1 Characteristics of trials included in the analysis
Ref.NCT numberCountry/regionsStudy periodNumber of patients
Chemotherapy regimen
CT
CT + TT
Valle et al[1], 2021NCT0271155318 countries and regionsaMay, 2016 to Aug, 2017101106CisGem
102
Vogel et al[17], 2018NCT01320254GermanyJul, 2011 to Dec, 20152862CisGem
Leone et al[18], 2016NCT01389414ItalyJun, 2010 to Sept, 20134445GemOx
Valle et al[19], 2015NCT00939848UKApr, 2011 to Sept, 20126062CisGem
Santoro et al[21], 2015NCT00753675ItalyOct, 2008 to Sept, 20125658Gemcitabine
Chen et al[20], 2015NCT01267344ChinaDec, 2010 to May, 20126062GemOx
Moehler et al[22], 2014NCT00661830GermanyMay, 2008 to Jul, 20114849Gemcitabine
Malka et al[23], 2014NCT00552149France and GermanyOct, 2007 to Dec, 20097476GemOx
Lee et al[24], 2012NCT01149122South KoreaFeb, 2009 to Aug, 2010133135GemOx